4.78
-0.1(-2.05%)
Currency In USD
| Previous Close | 4.88 |
| Open | 4.89 |
| Day High | 5.19 |
| Day Low | 4.7 |
| 52-Week High | 5.78 |
| 52-Week Low | 1.84 |
| Volume | 1.53M |
| Average Volume | 1.29M |
| Market Cap | 254.41M |
| PE | -3.54 |
| EPS | -1.35 |
| Moving Average 50 Days | 4.16 |
| Moving Average 200 Days | 3.15 |
| Change | -0.1 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $1.8 as of December 04, 2025 at a share price of $4.78. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $660.22 as of December 04, 2025 at a share price of $4.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achi
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
GlobeNewswire Inc.
Oct 29, 2025 12:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
GlobeNewswire Inc.
Oct 20, 2025 12:30 PM GMT
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasd